Prism Medico and Pharmacy Ltd

Book closure and AGM details

• Book closure from 13 September 2026 to 19 September 2026 (both days inclusive) for the AGM.
• Purpose: Annual General Meeting.
• Record date for e-voting: 12 September 2026.
• Remote e-voting starts 16 September 2026 at 09:00 AM.
• Remote e-voting ends 18 September 2026 at 05:00 PM.
• AGM scheduled for 19 September 2026 at 12:30 PM.
• Security type: equity shares.

IWPL investment and preferential issue variation

• Variation in objects of the preferential issue to fund acquisition of IWPL and create a subsidiary.
• Revised object: invest up to Rs 23 crore in IWPL via equity subscription; proceeds contingent on warrant exercise.
• IWPL project: LVP facility at Naraingarh, Haryana; capacity about 5.58 crore units; project ongoing.
• Prism to hold up to 71.32% of IWPL on a fully diluted basis; IWPL to become subsidiary.
• Funding source: proceeds from the May 5, 2026 preferential issue; variation subject to balance realized; no debt.
• Original objects discontinued; investment in IWPL replaces relevant allocations.
• Investment to be completed in one or more tranches within 24 months from approval.
• IWPL is related party; Sakshi Laller is promoter of IWPL; related parties abstain from voting.
• Value exceeds materiality threshold of 10% of turnover (Rs 24.70 lakh).
• Deviation/Variation to be disclosed to Audit Committee and stock exchanges; directors' report and annual report to reflect utilisation.

AGM Details

• AGM scheduled for 19 September 2026 at 12:30 PM via VC/OAVM.
• Record/Book closure from 13 to 19 September 2026 (inclusive).

Resolutions

• Resolution 1 (Ordinary): Adopt audited standalone financial statements and reports.
• Resolution 2 (Ordinary): Re-appoint Davender Singh as director on rotation.
• Resolution 3 (Ordinary): Re-appoint Garg Mendiratta and Associates as statutory auditors; remuneration to be fixed.
• Resolution 4 (Ordinary): Appoint SDK & Associates as Secretarial Auditors for five years.
• Resolution 5 (Special): Vary objects of the preferential issue and utilisation of proceeds.
• Resolution 6 (Special): Invest funds in Infuze Well Private Limited under Section 186.
• Resolution 7 (Ordinary): Approve material related party transaction — Infuze Well subscription.
• Resolution 8 (Ordinary): Approve related party transactions up to Rs 70 crores.

Director Changes

• Re-appoint Davender Singh (DIN: 09447213) as director.

Auditor Appointments

• Statutory auditors Garg Mendiratta and Associates to hold office until next AGM.
• Secretarial auditors M/S SDK & Associates to serve for five years (FY 2026-27 to 2030-31).

Material Related Party Transactions

• IWPL investment: subscription to up to 2.30 million equity shares for up to Rs 23 crore.
• IWPL to become subsidiary; Prism to hold ~71.32% post-issue on fully diluted basis.
• Promoter group: Sakshi Laller promoter of IWPL; pre-issue 19.40% share.
• Funding from preferential issue proceeds; not from existing IWPL shareholders.
• Valuation: Rs 10 per IWPL share by independent valuer.

Voting Results

• Voting results not disclosed in filing.

Key approvals and actions

• Director's Report for FY ended 31 March 2026 approved.
• Notice for the 24th AGM scheduled 19 September 2026 at 12:30 PM via VC approved.
• Register of Members and Share Transfer Books closed 13–19 September 2026 for AGM.
• Record date for electronic voting fixed at 12 September 2026.
• Mast Ram Chechi appointed Scrutinizer for e-voting at AGM.
• Re-appointment of Garg Mendiratta and Associates as Statutory Auditors; remuneration fixed.
• Appointed SDK & Associates as Secretarial Auditors for 2026-27 to 2030-31.
• Investments to be made as per Section 186 of the Companies Act 2013.
• Variation in objects and utilization of proceeds of the Preferential Issue approved.

Meeting Details

• Board meeting on 24 August 2026 at 1:00 PM at registered office, Suketi Road, Kala Amb, Himachal Pradesh.

Key Agenda Items

• Consider and approve Director's Report for FY ended March 31, 2026.
• Fix date/time for 24th Annual General Meeting and approve the notice.
• Close Register of Members and Share Transfer Books for AGM.
• Appoint Scrutinizer for e-voting and poll at the AGM.
• Recommend re-appointment of Garg Mendiratta and Associates as statutory auditors; fix remuneration.
• Appoint secretarial auditors for five financial years FY2026-27 to FY2030-31.
• Consider and discuss any other routine matters.
• Consider appointment of M/s SDK & Associates, Practicing Company Secretaries.

Financial results approved

• Unaudited standalone results for quarter ended 30 June 2026 approved.
• Limited Review Report by the auditor signed and placed before the Board.
• Statement prepared under Indian Accounting Standards and LODR Regulation 33.

Signatory authority

• Director Davender Singh authorized to sign the financial statements and implement actions.

Segment reporting

• Company has a single operating segment; segment reporting not applicable.

Dematerialisation status

• No dematerialisation/rematerialisation requests were received during the reporting period.
• Requests, if any, were confirmed to depositories by the RTA as accepted or rejected.
• Securities dematerialised have been listed on the stock exchanges where the earlier issued securities are listed.
• Certificates received for dematerialisation were mutilated, cancelled after verification, and depository name substituted as registered owner.

NSC status in quarter

• No non-convertible securities outstanding during the quarter.
• No interest, dividend, or principal payments were due for the quarter ended June 30, 2026.
• No unpaid obligations on non-convertible securities at quarter-end.
• No payments were made as none were due.

NCS payments due in upcoming quarter

• No NCS payments due in the quarter July 1, 2026 to September 30, 2026.

Prism Medico and Pharmacy Limited trading window closed from July 01, 2026; will reopen 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.